36 studies found for:    Migraine AND 2 hours post-dose
Show Display Options
Rank Status Study
1 Completed
Has Results
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
Condition: Migraines
Interventions: Drug: Telcagepant 140 mg;   Drug: Talcagepant 280 mg;   Drug: Placebo
2 Completed
Has Results
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Condition: Migraine
Interventions: Drug: Telcagepant potassium 150 mg;   Drug: Telcagepant potassium 300 mg;   Drug: Zolmitriptan 5 mg;   Drug: Placebo to telcagepant 150 mg;   Drug: Placebo to tecagepant 300 mg;   Drug: Placebo to zolmitriptan 5 mg;   Drug: Rescue medication
3 Completed A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
Condition: Migraine
Interventions: Drug: MK-1602;   Drug: Placebo;   Drug: Rescue medication
4 Completed A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Condition: Migraine
Interventions: Drug: MK-1602;   Drug: Placebo;   Drug: Rescue medication
5 Completed
Has Results
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
Condition: Migraine
Interventions: Drug: MK0974 50 mg;   Drug: MK0974 150 mg;   Drug: MK0974 300 mg;   Drug: Comparator: Placebo
6 Completed
Has Results
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Conditions: Migraine Disorders;   Heart Disease;   Cerebrovascular Accident;   TIA (Transient Ischemic Attack);   Vascular Diseases;   Peripheral Vascular Diseases
Interventions: Drug: Telcagepant;   Drug: Acetaminophen/Paracetamol;   Drug: Placebo to Telcagepant;   Drug: Placebo to Acetaminophen/Paracetamol
7 Completed
Has Results
Migraine Study in Adolescent Patients
Condition: Migraine Disorders
Interventions: Drug: Sumatriptan and Naproxen Sodium;   Drug: Placebo
8 Completed
Has Results
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
Condition: Migraine
Interventions: Drug: Comparator: rizatriptan benzoate;   Drug: Comparator: Placebo
9 Completed
Has Results
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Condition: Migraine, Acute
Interventions: Drug: rizatriptan;   Drug: placebo
10 Completed
Has Results
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
Condition: Migraine
Interventions: Drug: Comparator: Rizatriptan;   Drug: Comparator: Placebo
11 Terminated Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches
Condition: Migraine Headache
Intervention: Drug: NPS 1776
12 Recruiting Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Condition: Acute Migraine
Interventions: Drug: Lasmiditan 100 mg;   Drug: Lasmiditan 200 mg;   Drug: Placebo  (matches lasmiditan doses)
13 Completed Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Conditions: Migraine Without Aura;   Migraine With Aura
Interventions: Drug: Placebo;   Drug: Eletriptan HBr 40 mg;   Drug: Eletriptan HBr 80 mg
14 Completed
Has Results
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
Condition: Migraine, Without Aura
Interventions: Drug: sumatriptan succinate / naproxen sodium;   Drug: Placebo
15 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Conditions: Migraine With or Without Aura;   Migraine Disorders;   Migraine, Acute
Interventions: Drug: Combination Product (sumatriptan succinate / naproxen sodium);   Drug: Placebo
16 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Conditions: Migraine With or Without Aura;   Migraine Disorders;   Migraine
Interventions: Drug: Placebo;   Drug: Combination Product (sumatriptan succinate/naproxen sodium)
17 Completed Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.
Condition: Migraine
Intervention: Drug: rizatriptan or placebo
18 Terminated Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Condition: Migraine
Interventions: Drug: BGC20-1531;   Drug: Lactose
19 Completed Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day
20 Completed Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years